0001697862FALSE2025-06-30Q2--12-310.33330.027830.25iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesiso4217:EURxbrli:pureargx:equityInstrumentargx:Yutr:Yargx:segmentargx:customer00016978622025-01-012025-06-3000016978622025-06-3000016978622024-12-3100016978622024-01-012024-06-3000016978622023-12-3100016978622024-06-300001697862ifrs-full:IssuedCapitalMember2023-12-310001697862ifrs-full:SharePremiumMember2023-12-310001697862ifrs-full:RetainedEarningsMember2023-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2023-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2023-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2023-12-310001697862ifrs-full:RetainedEarningsMember2024-01-012024-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-01-012024-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-01-012024-06-300001697862ifrs-full:IssuedCapitalMember2024-01-012024-06-300001697862ifrs-full:SharePremiumMember2024-01-012024-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-01-012024-06-300001697862ifrs-full:IssuedCapitalMember2024-06-300001697862ifrs-full:SharePremiumMember2024-06-300001697862ifrs-full:RetainedEarningsMember2024-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-06-300001697862ifrs-full:IssuedCapitalMember2024-12-310001697862ifrs-full:SharePremiumMember2024-12-310001697862ifrs-full:RetainedEarningsMember2024-12-310001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001697862ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2024-12-310001697862ifrs-full:EquityAttributableToOwnersOfParentMember2024-12-310001697862ifrs-full:RetainedEarningsMember2025-01-012025-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-01-012025-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-01-012025-06-300001697862ifrs-full:IssuedCapitalMember2025-01-012025-06-300001697862ifrs-full:SharePremiumMember2025-01-012025-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-06-300001697862ifrs-full:IssuedCapitalMember2025-06-300001697862ifrs-full:SharePremiumMember2025-06-300001697862ifrs-full:RetainedEarningsMember2025-06-300001697862ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001697862ifrs-full:ReserveOfSharebasedPaymentsMember2025-06-300001697862ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember2025-06-300001697862ifrs-full:EquityAttributableToOwnersOfParentMember2025-06-300001697862ifrs-full:TradeReceivablesMemberifrs-full:AccumulatedImpairmentMember2025-06-300001697862ifrs-full:TradeReceivablesMemberifrs-full:AccumulatedImpairmentMember2024-12-310001697862argx:TermAccountsMember2025-06-300001697862argx:TermAccountsMember2024-06-300001697862currency:EUR2025-06-300001697862argx:ShareBasedCompensationAwardTrancheOneMember2025-01-012025-06-300001697862argx:ShareBasedCompensationAwardTrancheTwoMember2025-01-012025-06-300001697862argx:StockOptionPlanMemberargx:NonExecutiveDirectorMember2025-01-012025-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2025-01-012025-06-3000016978622025-03-012025-03-3100016978622025-06-012025-06-300001697862ifrs-full:BottomOfRangeMember2025-03-012025-03-310001697862ifrs-full:TopOfRangeMember2025-03-012025-03-310001697862ifrs-full:BottomOfRangeMember2025-06-012025-06-300001697862ifrs-full:TopOfRangeMember2025-06-012025-06-3000016978622025-03-310001697862argx:BelgianTaxedBeneficiariesMember2025-01-012025-06-300001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:BottomOfRangeMember2025-01-012025-06-300001697862argx:BelgianTaxedBeneficiariesMemberifrs-full:TopOfRangeMember2025-01-012025-06-300001697862ifrs-full:BottomOfRangeMember2025-01-012025-06-300001697862ifrs-full:TopOfRangeMember2024-06-012024-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2024-01-012024-12-310001697862argx:IfrsRestrictedStockUnitsRsusMemberargx:NonExecutiveDirectorMember2024-01-012024-12-310001697862argx:IfrsRestrictedStockUnitsRsusMemberargx:NonExecutiveDirectorMember2025-01-012025-06-300001697862argx:IfrsRestrictedStockUnitsRsusMember2024-01-012024-06-300001697862argx:PerformanceStockUnitsPSUsMember2025-01-012025-06-300001697862argx:PerformanceStockUnitsPSUsMember2025-06-302025-06-300001697862argx:RebatesAndChargeBacksMember2024-12-310001697862argx:DistributionFeesAndProductReturnsMember2024-12-310001697862argx:RebatesAndChargeBacksMember2025-01-012025-06-300001697862argx:DistributionFeesAndProductReturnsMember2025-01-012025-06-300001697862argx:RebatesAndChargeBacksMember2025-06-300001697862argx:DistributionFeesAndProductReturnsMember2025-06-300001697862country:US2025-01-012025-06-300001697862country:US2024-01-012024-06-300001697862country:JP2025-01-012025-06-300001697862country:JP2024-01-012024-06-300001697862country:CN2025-01-012025-06-300001697862country:CN2024-01-012024-06-300001697862country:NL2025-01-012025-06-300001697862country:NL2024-01-012024-06-300001697862argx:RestOfTheWorldMember2025-01-012025-06-300001697862argx:RestOfTheWorldMember2024-01-012024-06-300001697862argx:OncoVerityInc.JointVentureMember2025-06-300001697862argx:OncoVerityInc.JointVentureMember2024-12-310001697862argx:ExecutiveDirectorsMember2025-01-012025-06-300001697862argx:PerformanceStockUnitsPSUsMemberargx:ExecutiveDirectorsMember2025-01-012025-06-300001697862argx:HalozymeTherapeuticsIncMember2019-02-280001697862argx:LonzaMemberargx:EfgartigimodMember2025-06-300001697862argx:FujifilmMemberargx:EfgartigimodMember2025-06-30
| | | | | | | | | | | | | | |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
|
FORM 6-K
|
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2025
Commission File Number: 001-38097
|
| ARGENX SE |
| (Translation of registrant’s name into English) |
| Laarderhoogtweg 25 1101 EB Amsterdam, the Netherlands. |
(Address of principal executive offices)
|
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ☐
|
| | | | |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐ |
| | | | |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ |
| | | | |
| | | | | | | | | | | | | | |
argenx SE |
On July 31, 2025, argenx SE (the “Company) issued a press release, unaudited first half-year financial results for 2025, which are further described in an Unaudited Interim Report for the Six Months Ended June 30, 2025, and an investor presentation copies of which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1 and Exhibit 99.2, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-225375, 333-258253, and 333-274721), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished. |
| | | | |
| | | | | | | | |
| EXHIBITS |
| Exhibit | | Description |
| 99.1 | | Press Release dated July 31, 2025 |
| 99.2 | | Unaudited Interim Report for the Six Months Ended June 30, 2025 |
| 99.3 | | Investor Presentation dated July 31, 2025 |
| 101.INS | | Inline XBRL Instance Document |
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | | Cover Page Interactive Data File (formatted as Inline XBRL) |
| | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | |
| | ARGENX SE |
Date: July 31, 2025 | By: | /s/ Hemamalini (Malini) Moorthy |
| | Hemamalini (Malini) Moorthy |
| | General Counsel |
| | |
